-
公开(公告)号：US08846933B2
公开(公告)日：2014-09-30
申请号：US14154239
申请日：2014-01-14
Applicant: Pfizer Inc.
Inventor： Matthew Frank Brown , Ye Che , Anthony Marfat , Michael Joseph Melnick , Justin Ian Montgomery , Usa Reilly
IPC: A61K31/44 , C07D401/00 , C07D409/04 , C07D417/12 , C07D405/10 , C07D417/10 , C07D405/04 , C07D213/64 , C07D417/04 , C07D211/86 , C07D401/04 , C07D401/10 , C07D403/04 , C07D413/12 , C07D401/08 , C07D413/10 , C07D401/12
CPC classification number: A61K31/4412 , A61K31/4439 , C07D211/86 , C07D213/64 , C07D401/04 , C07D401/08 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/10 , C07D409/04 , C07D413/10 , C07D413/12 , C07D417/04 , C07D417/10 , C07D417/12 , Y02A50/473
Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.
Abstract translation: 本发明涉及一类新的异羟肟酸衍生物，它们用作LpxC抑制剂，更具体地说是它们用于治疗细菌感染的用途。
-
公开(公告)号：US20140057919A1
公开(公告)日：2014-02-27
申请号：US14068956
申请日：2013-10-31
Applicant: Pfizer Inc.
Inventor： Usa Reilly , Michael Joseph Melnick , Matthew Frank Brown , Mark Stephen Plummer , Justin Ian Montgomery , Ye Che , Loren Michael Price
IPC: C07D405/04 , C07D213/64 , C07D401/04 , C07D401/10
CPC classification number: C07D405/04 , C07D213/64 , C07D213/69 , C07D401/04 , C07D401/10 , C07D405/12 , C07D413/10 , C07D417/12
Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.
Abstract translation: 本发明涉及一类新的异羟肟酸衍生物，它们用作LpxC抑制剂，更具体地，其用于治疗细菌感染。
-
公开(公告)号：US11981696B2
公开(公告)日：2024-05-14
申请号：US16980616
申请日：2019-03-14
Applicant: Pfizer Inc.
Inventor： Tamim Fehme Braish , Matthew Frank Brown , Ye Che , Richard Andrew Ewin , Timothy Allan Johnson , Michael Joseph Melnick , Justin Ian Montgomery , Mark Stephen Plummer , Loren Michael Price , Usa Reilly , Daniel Uccello
Abstract: The present invention is directed to a new fluoro-pyridinone hydroxamic acid phosphates and boronates of Formulae I, II and III
wherein Q is selected from the group consisting of —P(O)(OH)2, —P(O)(OH)(O−M+), —P(O)(O−M+)2 and —P(O)(O−)2M2+; M+ at each occurrence is a pharmaceutically acceptable monovalent cation; and M2+ is a pharmaceutically acceptable divalent cation and their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.-
Patent Agency Ranking
公开(公告)号：US20210017206A1
公开(公告)日：2021-01-21
申请号：US16980473
申请日：2019-03-14
Applicant: Pfizer Inc.
Inventor： Matthew Frank Brown , Ye Che , Anthony Marfat , Michael Joseph Melnick , Justin Ian Montgomery , Timothy Allan Johnson , Richard Andrew Ewin , Daniel Paul Uccello , Usa Reilly , Tamim Fehme Braish
IPC: C07F9/6558 , C07F9/58 , C07F5/04 , A61P31/04
Abstract: The present invention is directed to new pyridinone or pyrimidinone hydroxamic acid phosphates of Formula (1) and boronates of Formula (2), stereoisomers thereof; wherein Q is selected from the group consisting of —P(O)(OH)2, —P(O)(OH)(O−M+), —P(O)(O−M+)2 and —P(O)(O−)2M2+; M+ at each occurrence is a pharmaceutically acceptable monovalent cation; and M2+ is a pharmaceutically acceptable divalent cation; X is CH or N; and Z is as defined herein; and their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.
-
公开(公告)号：US20210017205A1
公开(公告)日：2021-01-21
申请号：US16980616
申请日：2019-03-14
Applicant: Pfizer Inc.
Inventor： Tamim Fehme Braish , Matthew Frank Brown , Ye Che , Richard Andrew Ewin , Timothy Allan Johnson , Michael Joseph Melnick , Justin Ian Montgomery , Mark Stephen Plummer , Loren Michael Price , Usa Reilly , Daniel Uccello
Abstract: The present invention is directed to a new fluoro-pyridinone hydroxamic acid phosphates and boronates of Formulae I, II and III wherein Q is selected from the group consisting of —P(O)(OH)2, —P(O)(OH)(O−M+), —P(O)(O−M+)2 and —P(O)(O−)2M2+; M+ at each occurrence is a pharmaceutically acceptable monovalent cation; and M2+ is a pharmaceutically acceptable divalent cation and their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.
-
公开(公告)号：US20140364398A1
公开(公告)日：2014-12-11
申请号：US14469657
申请日：2014-08-27
Applicant: Pfizer Inc.
Inventor： Matthew Frank Brown , Anthony Marfat , Michael Joseph Melnick , Usa Reilly
IPC: C07C317/50 , C07F9/09 , C07D239/26 , C07D231/12 , C07D233/36 , C07D213/30 , C07D213/56 , C07D261/08
CPC classification number: C07C317/50 , C07C317/44 , C07C317/46 , C07C317/48 , C07C323/65 , C07C2601/02 , C07C2601/08 , C07C2601/16 , C07C2601/18 , C07D213/30 , C07D213/56 , C07D215/06 , C07D231/12 , C07D231/56 , C07D233/36 , C07D239/26 , C07D261/08 , C07D263/08 , C07D263/20 , C07D295/03 , C07D335/02 , C07F9/09 , C07F9/12
Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.
Abstract translation: 本发明涉及一类新的异羟肟酸衍生物，它们用作LpxC抑制剂，更具体地说是它们用于治疗细菌感染的用途。
-
公开(公告)号：US08779148B2
公开(公告)日：2014-07-15
申请号：US14068956
申请日：2013-10-31
Applicant: Pfizer Inc.
Inventor： Usa Reilly , Michael Joseph Melnick , Matthew Frank Brown , Mark Stephen Plummer , Justin Ian Montgomery , Ye Che , Loren Michael Price
IPC: A61K31/44 , C07D211/72 , C07D413/10 , C07D417/12 , C07D213/64 , C07D405/12 , C07D213/69 , C07D405/04 , C07D401/04 , C07D401/10
CPC classification number: C07D405/04 , C07D213/64 , C07D213/69 , C07D401/04 , C07D401/10 , C07D405/12 , C07D413/10 , C07D417/12
Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.
-
公开(公告)号：US20140128363A1
公开(公告)日：2014-05-08
申请号：US14154239
申请日：2014-01-14
Applicant: Pfizer Inc.
Inventor： Matthew Frank Brown , Ye Che , Anthony Marfat , Michael Joseph Melnick , Justin Ian Montgomery , Usa Reilly
IPC: C07D413/10 , C07D211/86 , C07D401/04 , C07D403/04 , C07D401/10 , C07D401/12
CPC classification number: A61K31/4412 , A61K31/4439 , C07D211/86 , C07D213/64 , C07D401/04 , C07D401/08 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/10 , C07D409/04 , C07D413/10 , C07D413/12 , C07D417/04 , C07D417/10 , C07D417/12 , Y02A50/473
Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.023 seconds)
